Diarrhoea News and Research RSS Feed - Diarrhoea News and Research

Study may give health workers vital new evidence in fight against Ebola

Study may give health workers vital new evidence in fight against Ebola

One year after the first Ebola cases started to surface in Guinea, the latest findings from a Cochrane review show new ways of hydrating patients in critical care environments across the world. [More]
Second-line bosutinib well tolerated by Japanese patients

Second-line bosutinib well tolerated by Japanese patients

Phase I/II clinical trial data support the use of bosutinib as second- or third-line tyrosine kinase inhibitor therapy in Japanese patients with Philadelphia chromosome-positive chronic myeloid leukaemia. [More]
Antibiotic use by travellers may promote spread of drug-resistant 'super-bacteria'

Antibiotic use by travellers may promote spread of drug-resistant 'super-bacteria'

Treating travellers' diarrhoea with antibiotics can promote the spread of drug-resistant "super-bacteria". [More]
LUME-Lung 1 shows QoL, symptoms benefits

LUME-Lung 1 shows QoL, symptoms benefits

LUME-Lung 1 trial patients’ reports of symptoms and health-related quality of life support the use of second-line nintedanib for the treatment of advanced non-small-cell lung cancer. [More]
Amrubicin, carboplatin duo efficacious in thymic carcinoma, not invasive thymoma

Amrubicin, carboplatin duo efficacious in thymic carcinoma, not invasive thymoma

Combination therapy with amrubicin and carboplatin is moderately effective in patients with advanced thymic carcinoma, a Japanese study finds, but invasive thymoma patients do not benefit from this regimen. [More]
British scientists take major initiative to tackle Crohn's disease

British scientists take major initiative to tackle Crohn's disease

British scientists are playing a key role in a global quest to find the causes of an incurable bowel condition. [More]

Elsevier launches new virtual journal: Atlas

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of a new virtual journal: Atlas. Published as a virtual journal, Atlas selects already published research on topics that hold high societal relevance or address global issues, and summarizes and presents the science in a lay-friendly, story format to reach an as wide as possible global audience. [More]
Long-term axitinib in RCC effective with ‘controllable’ toxicities

Long-term axitinib in RCC effective with ‘controllable’ toxicities

Axitinib treatment is effective in the long-term in Japanese patients with metastatic renal cell carcinoma and has manageable toxicity, a phase II study suggests. [More]
New analysis finds global improvements in life expectancy

New analysis finds global improvements in life expectancy

Global life expectancy increased by 5.8 years in men and 6.6 years in women between 1990 and 2013, according to a major new analysis from the Global Burden of Disease Study 2013 (GBD 2013). [More]
Figitumumab development discontinued for non-adenocarcinoma NSCLC

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Adding the novel insulin-like growth factor 1 receptor inhibitor figitumumab to the epidermal growth factor receptor–tyrosine kinase inhibitor erlotinib does not improve survival in patients with non-adenocarcinoma non-small-cell lung carcinoma, research shows. [More]
First-line dacomitinib may improve advanced NSCLC survival

First-line dacomitinib may improve advanced NSCLC survival

Preliminary research suggests that the second-generation tyrosine kinase inhibitor dacomitinib may improve progression-free survival in patients with advanced non-small-cell lung cancer with epidermal growth factor receptor mutations. [More]

Study indicates major added benefit of propranolol in some children with haemangioma

The Institute for Quality and Efficiency in Health Care (IQWiG)investigated in a dossier assessment whether propranolol offers an added benefit in comparison with the appropriate comparator therapy in infants with proliferating infantile haemangioma (sometimes called "strawberry mark"). [More]
Simple treatments for Ebola patients not given sufficient priority

Simple treatments for Ebola patients not given sufficient priority

The widespread misconception that there are no proven treatments for Ebola virus disease has meant that simple treatments – especially intravenous fluids and electrolytes, which could reduce the number of deaths caused by the virus – have been neglected, according to a new Comment, published in The Lancet. [More]
Dacomitinib ‘not superior’ to erlotinib in advanced NSCLC

Dacomitinib ‘not superior’ to erlotinib in advanced NSCLC

Dacomitinib, an irreversible, pan-epidermal growth factor receptor tyrosine kinase inhibitor, does not improve outcomes compared with the first-generation EGFR–TKI erlotinib in patients with advanced non-small-cell lung cancer, irrespective of their KRAS mutation status, finds the ARCHER 1009 study. [More]
New drug shows promise against treatment-resistant non-small cell lung cancer

New drug shows promise against treatment-resistant non-small cell lung cancer

A new drug that targets not only common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I/II clinical trial. [More]
Study reveals ETEC bacteria's genetic composition

Study reveals ETEC bacteria's genetic composition

Enterotoxigenic Escherichia coli (ETEC) bacteria are responsible each year for around 400 million cases of diarrhoea and 400,000 deaths in the world's low- and middle-income countries. Children under the age of five are most affected. [More]
Griffith University receives significant funding boost to combat pneumonia

Griffith University receives significant funding boost to combat pneumonia

Griffith University’s bid to fight the childhood killer pneumonia has received a significant boost following the award of a $304,000 grant from the Bill & Melinda Gates Foundation. [More]
MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

Merck Sharp & Dohme Ltd. MSD (known as Merck & Co., Inc. in the United States and Canada), today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection. [More]
Specific complex carbohydrates in human milk protect against Norovirus

Specific complex carbohydrates in human milk protect against Norovirus

Norovirus is the most common cause of viral epidemic gastroenteritis. About 18% of all gastroenteritis infections are caused by Norovirus affecting 267 million people worldwide every year. According to information of the Robert Koch-Institute more than 200.000 Norovirus-infections were registered in Germany during 2012 and 2013. The Centers for Disease Control and Prevention report up to 21 million Norovirus-infections per year in the USA. [More]
Obeticholic acid drug shows promise against bile acid diarrhoea

Obeticholic acid drug shows promise against bile acid diarrhoea

A pilot study testing a new type of drug in patients with chronic diarrhoea has shown promising effects on reducing their symptoms. [More]